---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-25-000060"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:34:51.074704+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Caribou Q2 net loss $54.1M ($0.58/sh); clinical data on track for H2 2025

## Summary
- GAAP net loss $54.1M ($0.58/sh) vs $37.7M ($0.42/sh) in Q2 2024; non-GAAP loss $32.8M ($0.35/sh) excluding $21.3M impairment.
- Cash $183.9M as of June 30, down from $249.4M at Dec 31; expected to fund operations into H2 2027.
- Completed enrollment of 20-patient confirmatory cohort for CB-010 in 2L LBCL; data and pivotal trial plans expected H2 2025.
- Completed dose escalation enrollment for CB-011 CaMMouflage trial in r/r MM; dose expansion data expected H2 2025.
- R&D expenses fell to $27.7M from $35.5M due to pipeline prioritization and workforce reduction; G&A down to $10.4M.

## SEC filing metadata
- accession: 0001619856-25-000060
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000060/0001619856-25-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000060/crbu-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-25-000060
- JSON: https://secwatch.observer/filing/0001619856-25-000060.json
- Plain text: https://secwatch.observer/filing/0001619856-25-000060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.